E-MECH LIMITED
Company number 08247762 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: E-MECH LIMITED
1. Financial Health Score: A-
E-MECH Limited is in excellent financial health, demonstrating the vitality of a well-conditioned athlete rather than a patient with any chronic conditions. The company has achieved remarkable, sustained growth over the past decade, with net assets expanding more than tenfold from £202,051 in 2015 to £2,210,880 in 2024. The only factor preventing a perfect score is the elevated concentration of debtors in the asset base, which represents a potential vulnerability requiring monitoring — much like slightly elevated blood pressure in an otherwise fit individual.
2. Key Vital Signs
Heart Rate: Revenue Growth & Profitability
| Metric | 2024 | 2023 | 2022 | Change |
|---|---|---|---|---|
| Net Assets | £2,210,880 | £1,697,755 | £1,319,569 | +30% YoY |
| Retained Earnings Growth | ~£513,125 | ~£378,186 | ~£429,715 | Strong profitability |
| Shareholders' Funds | £2,210,880 | £1,697,755 | £1,319,569 | Consistent equity building |
Diagnosis: The company's "heart" is beating strongly. Year-over-year retained earnings growth indicates healthy, consistent profitability. The 2024 profit of approximately £513,000 represents the company's strongest year on record.
Blood Pressure: Liquidity & Working Capital
| Metric | 2024 | 2023 | Interpretation |
|---|---|---|---|
| Current Assets | £2,975,665 | £2,400,235 | Strong resource base |
| Current Liabilities | £865,884 | £813,622 | Manageable obligations |
| Net Current Assets | £2,109,781 | £1,586,613 | Excellent working capital |
| Current Ratio | 3.44x | 2.95x | Very healthy liquidity |
| Cash Position | £740,498 | £524,310 | Strong and improving |
Diagnosis: Blood pressure is in the optimal range. A current ratio of 3.44x means the company has £3.44 of current assets for every £1 of current liabilities — well above the typical healthy threshold of 1.5x. Cash reserves have grown 41% year-over-year, indicating strong cash generation.
Cholesterol: Leverage & Debt Burden
| Metric | 2024 | 2023 | Interpretation |
|---|---|---|---|
| Total Liabilities | £865,884 | £813,622 | Moderate increase |
| Net Assets | £2,210,880 | £1,697,755 | Strong equity base |
| Debt-to-Equity Ratio | 0.39x | 0.48x | Conservative leverage |
| Long-term Liabilities | £24,975 | £42,678 | Reducing |
| Provisions | £20,700 | £19,958 | Stable |
Diagnosis: Cholesterol levels are excellent. The debt-to-equity ratio of 0.39x means the company has nearly £2.60 of equity for every £1 of debt — a very conservative capital structure. Long-term liabilities have actually decreased, and the company is not over-leveraged.
Bone Density: Asset Composition
| Asset Category | 2024 Value | % of Total | 2023 Value | % of Total |
|---|---|---|---|---|
| Fixed Assets | £146,774 | 4.9% | £173,778 | 7.2% |
| Stocks | £178,199 | 6.0% | £91,987 | 3.8% |
| Debtors | £2,056,968 | 69.1% | £1,783,938 | 74.3% |
| Cash | £740,498 | 24.9% | £524,310 | 21.8% |
| Total Assets | £2,975,665 | 100% | £2,400,235 | 100% |
Diagnosis: This is the one area requiring attention. Debtors represent nearly 70% of total assets — a significant concentration risk. While this has improved slightly from 74.3% in 2023, it remains high. Think of this as having one joint carrying most of the body's weight — it works, but it's a vulnerability.
3. Diagnosis: Overall Financial Condition
Strengths (Signs of Robust Health)
1. Exceptional Growth Trajectory The company has demonstrated a remarkable compound growth story: - Net assets have grown from £202,051 (2015) to £2,210,880 (2024) - This represents a compound annual growth rate of approximately 30.7% over 9 years - Growth has been consistent, with only minor dips in 2019-2020 (likely pandemic-related)
2. Strong Cash Generation Cash reserves have transformed dramatically: - 2020: £33,742 (a low point) - 2021: £33,616 - 2022: £405,876 - 2023: £524,310 - 2024: £740,498
The company has moved from being cash-constrained to holding over £740k in cash — a transformation from "living paycheque to paycheque" to having a healthy financial cushion.
3. Profitable Operations Each year shows retained earnings growth, meaning the company is consistently profitable and retaining profits rather than distributing them. This builds financial resilience.
4. Conservative Capital Structure With minimal long-term debt (£24,975) and strong equity, the company has significant borrowing capacity should it wish to fund expansion.
Symptoms Requiring Monitoring
1. High Debtor Concentration (Elevated Risk Marker) Debtors at £2,056,968 represent 69% of total assets. This could indicate: - Long payment terms with clients - Potential collection challenges - Revenue recognition timing - Industry norms for engineering consultancy (which typically have high work-in-progress)
Note: For engineering activities (SIC 71129), high debtor levels can be normal due to milestone billing and project-based work. However, the concentration remains a risk factor.
2. Stock Increase Stocks have nearly doubled from £91,987 to £178,199 (94% increase). This warrants monitoring to ensure stock remains current and realisable.
3. Limited Capital Investment Fixed assets have decreased from £173,778 to £146,774, suggesting the company may not be investing heavily in new equipment. For an engineering firm, this could indicate either efficient asset utilisation or potential future investment needs.
4. Prognosis: Future Financial Outlook
Short-term Outlook (12 months): Excellent
The company enters 2025 with strong momentum, healthy cash reserves, and a robust balance sheet. The immediate financial health is very strong.
Medium-term Outlook (2-3 years): Very Good
The consistent growth trajectory suggests continued expansion. However, the company will need to manage: - Working capital as the business grows - Potential need for capital investment in equipment - Debtor management to maintain cash flow
Long-term Considerations
As a small company with two equal shareholders/directors, key-person risk exists. Succession planning and business continuity arrangements would be prudent.
5. Recommendations: Prescriptions for Continued Financial Wellness
Priority 1: Debtor Management (Address the Elevated Risk)
- Review credit terms: Ensure payment terms are competitive but protective (30 days maximum where possible)
- Implement systematic collection procedures: Regular aged debtor reviews and escalation protocols
- Consider invoice financing: If debtor levels are structural to the business model, this could accelerate cash collection
- Target: Reduce debtor days and aim for debtors below 60% of total assets
Priority 2: Cash Utilisation Strategy
With £740k in cash and growing, consider: - Short-term deposit accounts: Earn interest on surplus cash - Strategic investment: Evaluate whether equipment upgrades could improve operational efficiency - Pension planning: Directors should consider tax-efficient pension contributions - Emergency reserve: Maintain 3-6 months of operating expenses as a buffer
Priority 3: Fixed Asset Investment Review
- Assess whether ageing plant and machinery needs replacement
- Evaluate lease vs. buy decisions for any new equipment
- Consider whether current asset levels support the growth trajectory
Priority 4: Stock Management
- Review the 94% increase in stock levels
- Ensure stock remains current and saleable
- Implement just-in-time procurement where possible
Priority 5: Business Continuity Planning
- Given the two-director structure with equal ownership, formalise shareholder agreements
- Consider key-person insurance
- Document succession plans
Growth Trajectory Summary
| Year | Net Assets | YoY Growth | Cash Position |
|---|---|---|---|
| 2015 | £202,051 | — | £23,384 |
| 2016 | £266,434 | +32% | £16,850 |
| 2017 | £526,795 | +98% | £61,855 |
| 2018 | £768,224 | +46% | £210,799 |
| 2019 | £672,876 | -12% | £22,076 |
| 2020 | £622,634 | -7% | £33,742 |
| 2021 | £889,284 | +43% | £33,616 |
| 2022 | £1,319,569 | +48% | £405,876 |
| 2023 | £1,697,755 | +29% | £524,310 |
| 2024 | £2,210,880 | +30% | £740,498 |